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Introduction: The non-interventional International Operations Hypoglycemia Assessment 
Tool (IO-HAT) study assessed the incidence of hypoglycemia in patients with insulin-treated 
diabetes across nine countries, including a cohort of patients in Colombia.
Materials and methods: Hypoglycemia incidence among patients with insulin-treated 
diabetes was assessed across 26 sites in Colombia. Hypoglycaemic events (any, nocturnal 
or severe) were reported in self-assessment questionnaires (SAQ) and patient diaries 
based on capillary blood glucose measurement or symptoms. Retrospective events (severe 
events 6 months before baseline and any event 4 weeks before baseline) were recorded in 
SAQ, Part 1, and prospective events (4 weeks from baseline) were recorded in SAQ, Part 
2, and patient diaries. Differences in hypoglycemia incidence reported in the retrospective 
and prospective periods were assessed using two-sided tests. 
Results: Of the 664 patients assessed, 213 had type 1 diabetes (T1D) and 451 had type 
2 diabetes (T2D). Nearly all patients experienced at least one hypoglycaemic event in the 
prospective period (97.1% T1D; 93.3% T2D). Rates of hypoglycemia (events per person-
year, PPY) were higher prospectively than retrospectively for any hypoglycemia (T1D: 121.6 
vs. 83.2, p<0.001; T2D: 28.1 vs. 24.6, p=0.127) and severe hypoglycemia (T1D: 15.3 vs. 
9.2, p=0.605; T2D: 9.5 vs. 3.5 p=0.040).
Conclusion: These results, the first from a patient-reported dataset on hypoglycemia in 
insulin-treated patients with diabetes in Colombia, show that patients reported higher rates 
of any hypoglycemia during the prospective period.
Clinical trial registration number: NCT02306681
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Encuesta sobre hipoglucemia en pacientes con diabetes tratados con insulina: la 
población colombiana del International Operations Hypoglycemia Assessment Tool
Introducción. En el estudio no intervencionista International Operations Hypoglycemia 
Assessment Tool (IO-HAT), se evalúo la incidencia de hipoglucemia en pacientes 
diabéticos tratados con insulina en nueve países, incluido Colombia.
Materiales y métodos. La incidencia de hipoglucemia entre pacientes diabéticos tratados 
con insulina se evaluó en 26 centros médicos en Colombia. Los episodios de hipoglucemia 
determinados con base en la medición de la glucemia capilar o en los síntomas se 
reportaron en el cuestionario de autoevaluación (Self-Assessment Questionnaire, SAQ) y en 
el diario del paciente. Los episodios retrospectivos (episodios graves y cualquiera ocurrido 6 
meses y 4 semanas antes del inicio del estudio, respectivamente) se registraron en el SAQ, 
parte 1, y los eventos prospectivos (4 semanas desde el inicio), en el SAQ, parte 2, y en el 
diario del paciente. Las diferencias en la incidencia de la hipoglucemia entre los períodos 
retrospectivo y prospectivo se evaluaron mediante una prueba de dos colas.
Resultados. De los 664 pacientes evaluados, 213 tenían diabetes de tipo 1 y 451 tenían 
diabetes de tipo 2. Casi todos los pacientes experimentaron al menos un episodio de 
hipoglucemia en el período prospectivo (97,1 %, diabetes de tipo 1, y 93,3 %, diabetes de tipo 
2). Los índices de hipoglucemia (episodios año-persona) fueron mayores prospectivamente 
que retrospectivamente para cualquier tipo de hipoglucemia (diabetes de tipo 1: 121,6 Vs. 
83,2; p<0,001; la diabetes de tipo 2: 28,1 Vs. 24,6; p=0,127) y para la hipoglucemia grave 
(diabetes de tipo 1: 15,3 Vs. 9,2; p=0,605; diabetes de tipo 2: 9,5 Vs. 3,5; p=0,040).
Conclusión. Estos resultados, que constituyen el primer conjunto de datos sobre hipoglucemia 
informados por pacientes diabéticos colombianos tratados con insulina, evidenciaron tasas 
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más altas para ambos tipos de hipoglucemia durante el período prospectivo.
Número de registro del ensayo clínico: NCT02306681
Palabras clave: hipoglucemia; diabetes mellitus; sistemas de infusión de insulina; Colombia.
In 2010, the overall prevalence of diabetes in Colombia was reported to be 
4-8% depending on the age range of the population studied (1). As with many 
countries around the world, this prevalence is increasing and more recently, 
the International Diabetes Federation (IDF) estimated there were over 3 million 
adults with diabetes in Colombia in 2015 with a national prevalence of 9.6% 
among adults aged 20-79 years and an annual average diabetes-related cost 
per person of USD$ 772.9 (2). It is estimated that the number of people with 
diabetes in Latin America will increase by 148% between 2000 and 2030 (1).
The key goal in the management of diabetes is to maintain normal blood 
glucose levels. Insulin therapy is used in the treatment of type 1 diabetes (T1D), 
and less commonly in the treatment of type 2 diabetes (T2D). Hypoglycemia is a 
frequent side effect of insulin therapy and is a major limiting factor in achieving 
good glycaemic control (3). This condition impacts the patient’s quality of life 
(4) and can result in increased morbidity (3) and mortality (5). Besides, its 
treatment represents a significant burden on the healthcare system (6).
Data on hypoglycemia rates in real-world practice, particularly in 
developing countries, are limited. Randomized clinical trials (RCT) often 
exclude patients with comorbidities or frequent episodes of hypoglycemia, 
which means that hypoglycemia rates reported from these RCTs are not 
representative of those in everyday clinical practice (7).
The global Hypoglycemia Assessment Tool (HAT) study, which was 
designed to determine the incidence of hypoglycemia in a global insulin-treated 
patient population, demonstrated that the real-world incidence of hypoglycemia 
is high compared with rates reported from randomized clinical trials. The study 
also showed there are regional differences in hypoglycemia incidence, with the 
highest rates being observed among patients with T1D in Latin America (8).
The Global Attitude of Patients and Physicians 2 (GAPP2) survey, which 
evaluated data on self-treated hypoglycemia in patients with T2D in seven 
countries (9), reported that self-treated hypoglycemia in Argentina was 
relatively common in patients using basal insulin analogs –at least one event 
in the previous 30 days was reported by 31% of patients with diabetes (9). In 
the Brazilian cohort of the HAT study, 91.7% of patients with T1D and 61.8% 
of patients with T2D reported at least one hypoglycaemic event during the 
4-week prospective observation period (10).
The International Operations (IO) HAT (IO-HAT) study builds on the 
information collected from the global HAT study and was designed to assess the 
incidence of hypoglycemia in patients with T1D or T2D treated with insulin (premix, 
short-acting, long-acting or sensor-augmented pump [SAP]) in Bangladesh, 
Colombia, Egypt, Indonesia, Philippines, Singapore, South Africa, Turkey, and the 
United Arab Emirates. The current analysis evaluates data from the Colombian 
cohort of insulin-treated patients with diabetes enrolled in the IO-HAT study.
Materials and methods
This was an international, multicentre non-interventional, 6-month 
retrospective and 4-week prospective study of hypoglycaemic events 
conducted across 26 sites in Colombia using self-assessment questionnaires 
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(SAQ) and patient diaries. The study was conducted in accordance 
with the Declaration of Helsinki (11) and the Guidelines for Good 
Pharmacoepidemiology Practices (12) and it was approved by country-
specific regulatory and ethics agencies as applicable.
Study population 
Eligible patients were enrolled consecutively during a routinely scheduled 
clinical consultation with their healthcare provider. Patients were eligible for 
the study if they were ≥18 years of age at baseline, had T1D/T2D treated with 
insulin for >12 months and had provided informed consent. Patients were 
excluded from the study if they were non-ambulatory, illiterate or otherwise 
unable to complete the written survey. 
Study endpoints
The primary endpoint of the study was to determine the percentage of patients 
who experience at least one hypoglycaemic episode during the 4-week prospective 
observational period among the insulin-treated patients with T1D or T2D.
Secondary endpoints included the incidence of hypoglycemic events, 
the relationship between patient demography, diabetes treatment, and the 
incidence of hypoglycemic episodes. The use of health system resources 
(number of hospital admission days, additional clinic appointments, and 
telephone contacts as a result of hypoglycaemic episodes) was assessed. 
The impact on patient behaviors as a result of hypoglycemia was assessed by 
the number of consultations with a doctor or nurse, increased calorie intake, 
avoidance of physical exercise, reduced or skipped insulin doses, increase in 
the frequency of blood glucose monitoring as a result of fear of hypoglycemia 
(continuous on scale of 0-10 where 0 is not afraid at all and 10 is absolutely 
terrified) or hypoglycaemic episodes, and any sick leave, sick days or short 
days as a result of hypoglycaemic episodes. 
Assessments
The assessment was by a two-part SAQ consisting of a retrospective cross-
sectional evaluation (Part 1) and a prospective observational evaluation (Part 2). 
Patient diaries were also provided to assist recall and to record hypoglycemic 
events, the effect of hypoglycemia on productivity, and healthcare utilization and 
productivity over the 4 weeks following study entry. The SAQs used for IO-HAT 
were similar to those used in the global HAT study with modifications to collect 
additional data on variables such as comorbidities, type of diabetes treatment 
used, loss of productivity, and quality of life. Paired responses to the Part 1 and 
Part 2 SAQs were used to estimate any differences in reporting of hypoglycemia 
between the retrospective and prospective periods.
Hypoglycemia classification
Severe hypoglycemia was defined as a hypoglycaemic event requiring 
third party assistance, which is consistent with the American Diabetes 
Association (ADA) definition (13).
Non-severe hypoglycemia was defined as an episode managed by the 
patient alone. 
Any hypoglycemic event was defined as the sum of severe and non-
severe hypoglycemia.
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Nocturnal hypoglycemia was defined as hypoglycemia occurring between 
midnight and 06:00 h.
A combined measure of any hypoglycemia (based on the sum of all 
hypoglycaemic events) was derived from both the patient diary and SAQ entries.
Hypoglycemia awareness
Hypoglycemia awareness (as defined by Pedersen (14) and as per 
protocol definition) was evaluated using the responses to the question: 
“How often do you have symptoms when you have a low blood sugar 
measurement?” and where the response “always” or “usually” denoted 
‘normal’ hypoglycemia awareness, “occasionally” denoted ‘impaired’ 
awareness, and “never” denoted ‘severely impaired’ awareness.
Statistical analysis
All statistical tests were two-sided and regarded as exploratory. Statistical 
significance was set at p<0.05 and no adjustments were made for multiple 
comparisons. The percentage of patients experiencing at least one 
hypoglycaemic event during the observation period was calculated together 
with the 95% confidence interval (CI) for this percentage. Binomial distribution 
was assumed. Data are presented as mean (SD) unless otherwise stated.
Ethical considerations 
The study protocol and assessments were conducted according to the 
Declaration of Helsinki and the International Conference on Harmonisation 
Good Clinical Practice Guidelines. The protocol was approved by independent 
ethics committees or institutional review boards before the start of the study. 
Signed informed consent was obtained from each patient before any study-
related activities. All study materials were translated into Spanish and the data 
obtained were translated back into English for analysis.
Results
Patient characteristics 
In the Colombian cohort, 664 patients completed the SAQ, Part 1, and 
were included in the full analysis set; 657 patients completed SAQ, Part 2, 
and were included in the completers analysis set; 653 patients completed 
patient diaries. Of the 664 patients completing the SAQ, Part 1, 213 had T1D 
and 451 had T2D. Patient characteristics are shown in table 1. Overall, 35.3% 
of patients were male. Patients with T2D were older than those with T1D 
(mean age, 63.2 years vs. 36.0 years, respectively). The duration of diabetes 
was longer in patients with T1D than T2D (17.2 years vs. 14.4 years). At 
baseline, patients with T1D had better levels of glycemic control than patients 
with T2D (HbA1c 7.7% in T1D and 8.4% in T2D).
Hypoglycemia 
Nearly all patients experienced at least one hypoglycaemic event in the 
4-week prospective observation period (97.1% of patients with T1D and 93.3% 
of those with T2D). The proportion of patients reporting a hypoglycaemic 
event in the prospective and retrospective periods is shown in figure 1. 
Hypoglycaemic rates (estimated number of events per patient-year [PPY]) of 
any and severe hypoglycemia were higher in the prospective period than in 
the retrospective period (figure 1).
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Number of patients who completed 
part 2 of SAQ, n (%) 
211 (99.1) 446 (98.9)
Sex: male/female, % 
Age, years 
BMI (kg/m2)
Duration of diabetes, years 
Duration of insulin use, years
HbA1c, %*
FBG, mg/dl
PPG, mg/dl
 32.9/65.7
  36.0 (13.6)
  24.7   (3.8)
  17.2 (10.1)
  16.1 (10.1)
    7.7   (1.4)
154.8 (64.8)
153.0 (77.4)
37.7/61.4
  63.2 (10.9)
  28.4   (4.9)
  14.4   (8.7)
    6.8   (5.9)
    8.4   (1.8)
136.8 (50.4)
180.0 (72.0)
Previous medical illnesses, n (%*)
Neuropathy
Retinopathy
Peripheral vascular disease
Nephropathy
Myocardial infarction
Angina
None}
  43    (20.2)
  47    (22.1)
  11      (5.2)
  41    (19.2)
    5      (2.3)
    5      (2.3)
122    (57.3)
194    (43.0)
181    (40.1)
  97    (21.5)
131    (29.0)
  58    (12.9)
  44      (9.8)
124    (27.5)
Method of diabetes treatment, n (%)
Short-acting insulin
Long-acting insulin 
Pre-mix
Both short and long acting
Both short acting and pre-mix
Both long acting and pre-mix
Short and long acting and pre-mix
Missing
  97    (45.5)
    8      (3.8)
    0
105    (49.3)
    0
    1      (0.5)
    0
    2      (0.9)
  15      (3.3)
173    (38.4)
    4      (0.9)
250    (55.4)
    5      (1.1)
    3      (0.7)
    0
    1      (0.2)
Use of insulin pump, n (%)
Yes 
No 
Other
  97    (45.5)
112     (52.6)
    4      (1.9)
  17      (3.8)
434    (96.2)
    0       (0)
Checks blood sugar levels, n (%)
Yes 
No 
Not sure
207    (97.2)
    4      (1.9)
    1      (0.5)
434    (96.2)
  12      (2.7)
    4      (0.9)
Table 1. Characteristics of the patient population
BMI: body mass index; FBG: fasting blood glucose; n: total number of subjects 
participating; PPG: postprandial glucose; SAQ: self-assessment questionnaire; 
SD: standard deviation; T1D: type 1 diabetes; T2D: type 2 diabetes
Data expressed as mean (SD) unless otherwise stated. 
* Percentages based on number of patients with evaluable data 
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Figure 1. Self-reported hypoglycemia rates
T1D: type 1 diabetes; T2D: type 2 diabetes 
* Retrospective data based on a 6-month period and prospective data based on a 4-week period
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The estimated incidence rate ratio (RR) for any hypoglycemia in the 
prospective and retrospective periods was 1.46 (p<0.001) for T1D and 
1.14 (p=0.127) for T2D. The proportion of patients reporting nocturnal 
hypoglycemia was higher retrospectively than prospectively in patients with 
T1D (51.7% vs. 50.5%) and T2D (23.1% vs. 13.5%). Nocturnal hypoglycemia 
rates were higher retrospectively in patients with T1D (29.6 events PPY 
vs. 21.3 events PPY, RR=0.72; p=0.036) and T2D (9.0 events PPY vs. 4.0 
events PPY, RR=0.43; p<0.001). The proportion of patients who defined 
hypoglycemia by using both blood glucose measurement and symptoms was 
49.3% in T1D and 30.6% in T2D.
Hypoglycemia incidence by insulin regimen
The incidence rates for any hypoglycemia by insulin regimen are shown in 
figure 2A and B. 
Figure 2. Estimated rate of (A) any hypoglycaemic event in T1D and (B), any hypoglycaemic 
event in T2D by insulin regimen
S+L: short-acting and long-acting insulin; T1D: type 1 diabetes; T2D: type 2 diabetes
* Data based on a 4-week period for both retrospective and prospective analyses 
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Healthcare utilization
Healthcare utilization as a result of hypoglycemia in the 6-month 
retrospective and 4-week prospective period is shown in figure 3A. Healthcare 
utilization was higher in the retrospective period than in the prospective 
period both in patients with T1D and T2D. In the prospective period, 
healthcare utilization (admission to hospital, additional clinic appointments, 
and telephone contact as a result of hypoglycemic episodes) was higher in 
patients with T1D than T2D.
Patient knowledge and behaviors
More patients with T1D than T2D indicated they had knowledge of 
hypoglycemia before reading the definition in the Part 1, SAQ (97.5% vs. 
78.7%, respectively). The proportion of patients who measured blood sugar 
to determine hypoglycemia but provided values that were inconsistent with 
standard definitions (≤3.9 mmol/L or ≤70 mg/dL) was higher in patients 
with T2D (12.9%) than those with T1D (4.9%). Patients with T1D had more 
hypoglycemia awareness than patients with T2D. Normal awareness was 
reported in 60.1% (T1D) vs. 32.4% (T2D) of patients, impaired awareness 
was reported by 37.6% (T1D) vs. 50.8% (T2D) and severely impaired 
awareness by 2.3% (T1D) vs. 12.0% (T2D).
Figure 3. (A) Healthcare utilization as a result of hypoglycemia. (B) Patient actions resulting from 
hypoglycemia in the retrospective and prospective periods
T1D: type 1 diabetes; T2D: type 2 diabetes 
* Retrospective data based on a 6-month period and prospective data based on a 4-week period. Bars represent the 
proportion of patients who answered ‘yes’.
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Patient actions as a result of hypoglycemia are shown in figure 3B. 
Patients with T1D were more likely than those with T2D to increase their blood 
glucose monitoring following a hypoglycaemic episode. With respect to fear of 
hypoglycemia, there were no notable differences between patients with T1D 
[mean (SD) score, 6.9 (2.98)] and T2D [mean (SD) score, 6.2 (3.28)].
Discussion
The prevalence of diabetes in Colombia is approximately 9.6% and 
this is estimated to rise to 12.9% by 2040 (2). Diabetes is the fifth leading 
cause of mortality in the country and the disease is also associated with 
high morbidity (15). Incidence of hypoglycemia is high in the Latin America 
region; the GAPP2 survey estimated that 31% of patients with diabetes in 
Argentina experienced at least one hypoglycaemic event in the previous 
30 days (9), whilst the Brazilian cohort of the HAT study reported 91.7% of 
patients with T1D and 61.8% of patients with T2D had experienced at least 
one hypoglycaemic event during the 4-week prospective observation period 
of the study (10).
In the current study, patients reported higher rates of overall and severe 
hypoglycemia during the prospective period. The difference in rates between 
the two periods may be a result of recall bias as patient diaries were provided 
to assist recall and record hypoglycaemic events during the prospective 
period whilst the retrospective data were based on the SAQ. In contrast, 
patients reported higher nocturnal rates of hypoglycemia in the retrospective 
period. It is possible that the definition of nocturnal hypoglycemia (between 
midnight and 06:00 h) may have been adhered to more strictly during the 
prospective period than the retrospective period. Patients may also have 
reported more episodes of nocturnal hypoglycemia retrospectively owing 
to recall bias and the belief that these events occur more frequently than 
they do. Furthermore, nocturnal hypoglycemia may be underreported as the 
patient diaries may be more difficult to complete at night than during the day. 
Overall, the results of our study suggest that the incidence of hypoglycemia 
may be underreported.
The incidence of hypoglycemia (all, nocturnal, and severe) in Colombian 
patients was high compared with the IO-HAT overall results (Emral, et al., 
in progress). It should be noted that Colombia is the only country which 
specifically categorized patients with T1D or T2D using insulin pumps. The 
high incidence of hypoglycemia in this cohort may be primarily driven by 
the use of insulin pumps with integrated continuous glucose monitoring, as 
patients are able to see their glucose readings constantly and, therefore, 
notice and report more hypoglycemia. Besides, as readings from pumps 
are not 100% accurate, the possibility of falsely low value (even though the 
patient is euglycemic) cannot be ruled out (16).
Colombia has one of the highest prevalence of adults with diabetes in 
South and Central America (17). Poor glycemic control, defined as HbA1c 
>7%, is a strong predictor of complications that result in increased resource 
usage within the region. One study assessing the quality of diabetic care in 
Colombia reported that only 42.9% of patients had HbA1c levels ≤7%, whilst 
21.1% of patients had HbA1c >9% (18). Mean HbA1c levels in the current 
study were >7% at baseline indicating poor glycaemic control. No association 
between HbA1c and hypoglycemia was identified in the current study, which 
suggests that hypoglycemia is common at all levels of glycaemic control.
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Hypoglycemia influences treatment compliance, which can result in 
an increase in complications due to lack of disease control as a result of 
modifying the insulin dose in response to hypoglycemia. In a 7-year study 
evaluating consistency in using diabetic medications in a Mexican American 
population, inconsistent use of medication was associated with an increased 
risk in kidney problems and death (19).
Patient actions as a result of hypoglycemia lead to an increase in the use 
of healthcare resources and the health economic burden (6). In particular, 
severe hypoglycaemic events often result in emergency/ambulance calls and 
hospital treatment, thereby incurring in substantial healthcare costs (20). The 
proportion of patients seeking medical advice or requiring hospitalization as a 
result of hypoglycemia was lower during the prospective period of the IO-HAT 
Colombian study, which may be explained by increased patient knowledge as 
a result of having participated in the study.
Our results suggest that increasing patient knowledge of hypoglycemia 
may reduce its impact on the healthcare system and enable patients to meet 
their individual treatment goals more effectively. Furthermore, the results of 
this study highlight the need for patient education regarding hypoglycemia 
and for actively promoting hypoglycaemic control in clinical practice.
As with any observational study, there are strengths and limitations to 
IO-HAT. Limitations include the short follow-up period of the study and the 
possibility of bias since hypoglycemia is self-reported by the patient based on 
patient recall of information, which may be less accurate for the retrospective 
period. However, this is also a strength of the study, as self-reporting captures 
information such as missed blood glucose tests or unawareness of the 
threshold at which blood glucose concentrations represent a hypoglycaemic 
event. In addition, the observational nature of the study means that the results 
reflect real-life practice.
Insulin is the mainstay of diabetes treatment, however, hypoglycemia 
remains a major obstacle in achieving good glycaemic control and fear of 
hypoglycemia can limit treatment intensification as a result of the patient’s 
unwillingness to take medication. New technologies, in particular the new 
generation longer-acting basal insulins have been shown to have significantly 
more predictable glucose-lowering effects and may help to lower the risk of 
hypoglycemia without compromising efficacy (21).
In conclusion, these results are the first patient-reported dataset on 
hypoglycemia in Colombia. Patients reported higher rates of hypoglycemia 
(any and severe) during the prospective period. This could be a result of recall 
bias during the retrospective study period or of increased patient knowledge 
on hypoglycemia due to their participation in the study. The results of our 
study are in line with the overall data from the IO-HAT study and indicate that 
hypoglycemia is underreported and, therefore, underestimated.
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